<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922633</url>
  </required_header>
  <id_info>
    <org_study_id>E3112-CP2</org_study_id>
    <nct_id>NCT03922633</nct_id>
  </id_info>
  <brief_title>A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants</brief_title>
  <official_title>A Phase 1 Clinical Study of a Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EA Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after
      a single intravenous dose of E3112 in Japanese healthy adult male participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Concentrations of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Serum Concentration of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Concentration (Cmax) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>Cmax is the maximum observed concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Concentration (Tmax) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>Tmax is the time from dosing to reach the maximum observed concentration a drug achieves in a specified compartment or test area of the body after the drug has been administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC 0-t) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>AUC 0-t is area under the concentration-time curve from time 0 to time of last quantifiable concentration for E3112.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC∞) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>AUC∞ is area under the concentration-time curve from time 0 to infinity of E3112.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of Elimination (t1/2) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>t1/2 is the time required for the concentration of the drug to reach half of its original value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>CL is defined as the rate of drug elimination divided by the plasma concentration of the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vd) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>Vd is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with an Abnormal, Clinically Significant Hematology parameter value</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with an Abnormal, Clinically Significant Clinical Chemistry Parameter Value</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with an Abnormal, Clinically Significant Urine Value</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change in Vital Signs</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change in Electrocardiogram (ECG)</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change in Physical Findings</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change in Ophthalmological Findings</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Serum Anti-E3112 Antibodies</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Male Participants</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E3112</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Cohort 1 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 1 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 2 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 3 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 4 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 5 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 5 Group B: Placebo + E3112</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Cohort 1 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 1 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 2 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 3 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 4 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 5 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 5 Group B: Placebo + E3112</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-smoking Japanese males aged 20 to 44 years at the time of written, informed
             consent

          2. Body Mass Index (BMI) at screening is 18.5 or more but less than 25.0 kilogram per
             square metre (kg/m^2)

          3. Written, informed consent to participate in the study based on the participant's own
             free will

          4. Willing and able to comply with the requirements in the study after being fully
             informed of the requirements

        Exclusion Criteria:

          1. Male participants with reproductive potential who and whose partner do not agree to
             practice medically appropriate contraception (Note: throughout the study)

          2. A history or complication of malignant tumor, lymphoma, leukemia, or
             lymphoproliferative disorder, a clinically significant disease requiring treatments
             within 8 weeks before the investigational product treatment, or a history of a
             clinically significant infection within 4 weeks before the investigational product
             treatment

          3. With a psychiatric, digestive, hepatic, renal, respiratory, endocrine, hematologic,
             neural, or cardiovascular disease within 4 weeks before the investigational product
             treatment, a congenital metabolic abnormality, or otherwise a disease that may affect
             the drug assessments

          4. With a surgical history (e.g., resection of the liver, kidney, or digestive tract,
             etc.) at screening that may affect the pharmacokinetics of the investigational product

          5. Suspicion of having a clinically abnormal symptom or an organ impairment that requires
             treatments based on the history/complications at screening or physical findings, vital
             signs, electrocardiogram findings, or laboratory values at screening or baseline

          6. Testing positive for human immunodeficiency virus (HIV) at screening

          7. A positive response to a qualitative test for hepatitis B virus surface antigen (HBs
             antigen), hepatitis B virus core antigen (HBc) antibody, hepatitis C virus (HCV)
             antibody, or syphilis

          8. Use of a prescription drug within 4 weeks before the investigational product treatment

          9. Use of an over-the-counter drug within 2 weeks before the investigational product
             treatment

         10. Receiving a vaccine within 4 weeks before the investigational product treatment

         11. Ongoing participation in another clinical study or use of an investigational product
             or device within 16 weeks before the investigational product treatment while
             participating in another clinical study

         12. Receiving blood transfusion within 12 weeks before the investigational product
             treatment, providing a whole-blood sample of 400 millilitre (mL) or more between 12 to
             4 weeks before the investigational product treatment or a whole-blood sample of 200 mL
             or more within 4 weeks before the investigational product treatment, or giving blood
             components by pheresis within 2 weeks before the investigational product treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>EA Pharma Co., Ltd., Public Relations Group, Corporate Planning Dept.</last_name>
    <phone>+81-(0)3-6280-9600</phone>
    <email>contact_ea@eapharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>EA Pharma Trial Site</name>
      <address>
        <city>Higashi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E3112</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Japanese</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

